Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

65 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
Vallejo C, Ríos E, de la Serna J, Jarque I, Ferrá C, Sánchez-Godoy P, Solano C, de la Cámara R, Rosell AI, Varela R, García MD, González-Barca E, López J, Pérez E, Ferrer S, Casado LF, Vázquez L, Villalón L, García-Marco JA. Vallejo C, et al. Among authors: villalon l. Expert Rev Hematol. 2011 Feb;4(1):9-16. doi: 10.1586/ehm.10.77. Expert Rev Hematol. 2011. PMID: 21322774
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, Pérez-López R, Ayala R, Vall-Llovera F, García-Gutierrez V, Gómez Casares MT, González San Miguel JD, Hernández-Rivas JÁ, Sánchez-Guijo F, Martínez-García AB, Villalón L, Conesa-García V, Rodriguez A, Casado F, Garcia-Gonzalez X, Sáez Perdomo MN, Baños Ú, Steegmann JL; CML Spanish Group (GELMC). Osorio S, et al. Among authors: villalon l. Ann Hematol. 2018 Nov;97(11):2089-2098. doi: 10.1007/s00277-018-3413-7. Epub 2018 Jun 28. Ann Hematol. 2018. PMID: 29955943 Clinical Trial.
Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M. Giraldo P, et al. Among authors: villalon l. Blood Cells Mol Dis. 2011 Jan 15;46(1):115-8. doi: 10.1016/j.bcmd.2010.09.005. Epub 2010 Oct 8. Blood Cells Mol Dis. 2011. PMID: 20934891
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E, Alvarez-Larrán A, López-Jiménez J, Osorio S, Villalón L, Camós M, García-Conde J, Odriozola J. Cervantes F, et al. Among authors: villalon l. Haematologica. 2003 Oct;88(10):1117-22. Haematologica. 2003. PMID: 14555307 Clinical Trial.
Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
Giraldo P, Andrade-Campos M, Alfonso P, Irun P, Atutxa K, Acedo A, Barez A, Blanes M, Diaz-Morant V, Fernández-Galán MA, Franco R, Gil-Cortes C, Giner V, Ibañez A, Latre P, Loyola I, Luño E, Hernández-Martin R, Medrano-Engay B, Puerta J, Roig I, de la Serna J, Salamero O, Villalón L, Pocovi M. Giraldo P, et al. Among authors: villalon l. Blood Cells Mol Dis. 2018 Feb;68:173-179. doi: 10.1016/j.bcmd.2016.10.017. Epub 2016 Oct 24. Blood Cells Mol Dis. 2018. PMID: 27836529
65 results